/NEO
NEO Stock - NeoGenomics, Inc.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$11.83+1.28%
+$0.15 (+1.28%) • Dec 19
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.98
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).87
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.56
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+18.3%upside
Target: $13.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NEO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.71 – $11.95
TARGET (TP)$14.00
STOP LOSS$10.88
RISK/REWARD1:2.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.59
52W High$19.11
52W Low$4.72
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $660.57M | $591.64M | $509.73M | $484.33M | $444.45M |
| Gross Profit | $290.10M | $244.60M | $187.90M | $187.06M | $185.89M |
| Gross Margin | 43.9% | 41.3% | 36.9% | 38.6% | 41.8% |
| Operating Income | $-92,106,000 | $-107,736,000 | $-157,623,000 | $-118,754,000 | $-13,992,000 |
| Net Income | $-78,726,000 | $-87,968,000 | $-144,250,000 | $-8,347,000 | $4.17M |
| Net Margin | -11.9% | -14.9% | -28.3% | -1.7% | 0.9% |
| EPS | $-3.10 | $-3.50 | $-5.80 | $-0.35 | $0.19 |
Company Overview
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
55%
Hold / Neutral
5
45%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
6 Bullish5 Neutral/Bearish
Price Targets
$19
Average Target
↑ 58.7% Upside
Now
$9
Low
$19
Average
$26
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 30th 2025 | BTIG Research | Downgrade | Neutral | - |
| July 29th 2025 | William Blair | Downgrade | Market Perform | - |
| May 15th 2025 | Guggenheim | Initiation | Neutral | - |
| April 30th 2025 | Leerink Partners | Downgrade | Market Perform | $9 |
| January 13th 2025 | The Benchmark Company | Downgrade | Hold | - |
| December 10th 2024 | Jefferies | Initiation | Buy | $22 |
| May 1st 2024 | Craig Hallum | Resumed | Buy | $26 |
| December 29th 2023 | BTIG Research | Reiterated | Buy | $21← $25 |
| August 21st 2023 | Stephens | Upgrade | Overweight | $18 |
| May 16th 2023 | Raymond James | Downgrade | Market Perform | - |
| May 9th 2023 | BTIG Research | Upgrade | Buy | $25 |
| February 24th 2023 | The Benchmark Company | Upgrade | Buy | $20 |
| February 1st 2023 | Needham | Upgrade | Buy | $15 |
| August 26th 2022 | The Benchmark Company | Downgrade | Hold | - |
| August 22nd 2022 | Needham | Downgrade | Hold | - |
Earnings History & Surprises
NEOBeat Rate
72%
Last 18 quarters
Avg Surprise
+80.0%
EPS vs Estimate
Beats / Misses
13/3
2 met exactly
Latest EPS
$0.03
Q4 2025
EPS Surprise History
Q1 24
+220.5%
$0.03vs$0.01
Q2 24
-59.2%
$-0.02vs$-0.01
Q3 24
+880.4%
$0.03vs$0.00
Q4 24
+316.7%
$0.05vs$0.01
Q1 25
+33.3%
$0.04vs$0.03
Q2 25
-300.0%
$-0.08vs$-0.02
Q3 25
0.0%
$0.03vs$0.03
Q4 25
+50.0%
$0.03vs$0.02
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Feb 17, 2026 | $0.04 | — | — | — |
Q4 2025 | Oct 28, 2025 | $0.02 | $0.03 | +50.0% | ✓ BEAT |
Q3 2025 | Jul 29, 2025 | $0.03 | $0.03 | 0.0% | = MET |
Q2 2025 | Apr 29, 2025 | $-0.02 | $-0.08 | -300.0% | ✗ MISS |
Q1 2025 | Feb 18, 2025 | $0.03 | $0.04 | +33.3% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $0.01 | $0.05 | +316.7% | ✓ BEAT |
Q3 2024 | Jul 29, 2024 | $0.00 | $0.03 | +880.4% | ✓ BEAT |
Q2 2024 | Apr 30, 2024 | $-0.01 | $-0.02 | -59.2% | ✗ MISS |
Q1 2024 | Feb 20, 2024 | $0.01 | $0.03 | +220.5% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.10 | $-0.05 | +50.0% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.14 | $-0.09 | +35.7% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-0.15 | $-0.06 | +60.0% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.19 | $-0.14 | +26.3% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.22 | $-0.16 | +27.3% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $-0.23 | $-0.20 | +13.0% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $-0.13 | $-0.14 | -7.7% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.08 | $-0.08 | 0.0% | = MET |
Q3 2021 | Aug 6, 2021 | $-0.05 | $-0.01 | +80.0% | ✓ BEAT |
Latest News
Natera Ends Lawsuit, Clearing Path for NeoGenomics' RaDaR ST Launch
📈 PositiveBenzinga•Dec 15, 2025, 12:24 PM
NeoGenomics To Present Data Utilizing Its RaDaR 1.0 Assay For Detection Of Molecular Residual Disease At 2025 SABCS
➖ NeutralBenzinga•Dec 10, 2025, 12:09 PM
NeoGenomics Data At ASH 2025 Shows Comprehensive Genomic Profiling Improves Diagnosis And Identifies Actionable Fusions In Myeloid Malignancies
📈 PositiveBenzinga•Dec 8, 2025, 01:08 PM
NeoGenomics To Present New Research Demonstrating High Concordance Between RaDaR ST And RaDaR 1.0 Assays For Detecting MRD In Solid Tumors, At ISLB Annual Congress 2025
📈 PositiveBenzinga•Oct 30, 2025, 04:53 PM
NeoGenomics Non-GAAP EPS of $0.03 beats by $0.01, revenue of $187.8M beats by $3.95M
📈 PositiveSeeking Alpha•Oct 28, 2025, 11:08 AM
NeoGenomics Affirms FY2025 Adj EPS Guidance of $0.08-$0.12 vs $0.09 Est
📈 PositiveBenzinga•Oct 28, 2025, 11:07 AM
NeoGenomics Q3 Adj. EPS $0.03 Beats $0.02 Estimate, Sales $187.797M Beat $183.770M Estimate
📈 PositiveBenzinga•Oct 28, 2025, 11:05 AM
NeoGenomics Presents Assay-Relevant Data To Showcase How Molecular Residual Disease Assay May Benefit Pharma Partners At ESMO Congress 2025
➖ NeutralBenzinga•Oct 14, 2025, 11:20 AM
TD Cowen Maintains Buy on NeoGenomics, Raises Price Target to $12
📈 PositiveBenzinga•Sep 12, 2025, 01:47 PM
Stephens & Co. Maintains Overweight on NeoGenomics, Raises Price Target to $11
📈 PositiveBenzinga•Sep 2, 2025, 11:35 AM
Needham Maintains Buy on NeoGenomics, Raises Price Target to $14
📈 PositiveBenzinga•Aug 29, 2025, 06:27 PM
NeoGenomics shares are trading higher after the company announced that the District Court for the Middle District of North Carolina has granted motion for summary judgement that all of Natera's asserted patent claims are invalid for claiming ineligible subject matter.
📈 PositiveBenzinga•Aug 29, 2025, 12:54 PM
NeoGenomics rallies after court win in Natera patent dispute
📈 PositiveSeeking Alpha•Aug 29, 2025, 12:45 PM
Natera Patent Claims Against NeoGenomics' RaDaR v1.1 Invalidated; Company Weighs Appeal, Further Enforcement
📉 NegativeBenzinga•Aug 29, 2025, 12:21 PM
NeoGenomics Secures Court Ruling Invalidating Natera's Patents; Case Dismissed With Prejudice
📈 PositiveBenzinga•Aug 29, 2025, 11:11 AM
NeoGenomics drops as sequential revenue decline leads to Q1 miss
📉 NegativeSeeking Alpha•Apr 29, 2025, 04:02 PM
Frequently Asked Questions about NEO
What is NEO's current stock price?
NeoGenomics, Inc. (NEO) is currently trading at $11.83 per share. The stock has moved +1.28% today.
What is the analyst price target for NEO?
The average analyst price target for NEO is $14.00, based on 1 analyst.
What sector is NeoGenomics, Inc. in?
NeoGenomics, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is NEO's market cap?
NeoGenomics, Inc. has a market capitalization of $0.30 billion, making it a small-cap company.
Does NEO pay dividends?
No, NeoGenomics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACRS
Aclaris Therapeutics, Inc.
$3.14
Mkt Cap: $0.3B
ARCT
Arcturus Therapeutics Holdings Inc.
$6.53
Mkt Cap: $0.2B
HUMA
Humacyte, Inc.
$1.11
Mkt Cap: $0.2B
MDXH
MDxHealth S.A.
$3.15
Mkt Cap: $0.2B
QTRX
Quanterix Corporation
$6.59
Mkt Cap: $0.3B
SGMT
Sagimet Biosciences Inc.
$6.28
Mkt Cap: $0.2B
SMTI
Sanara MedTech Inc.
$24.21
Mkt Cap: $0.2B
STXS
Stereotaxis, Inc.
$2.34
Mkt Cap: $0.2B
TKNO
Alpha Teknova, Inc.
$4.65
Mkt Cap: $0.2B
XGN
Exagen Inc.
$6.43
Mkt Cap: $0.1B
Explore stocks similar to NEO for comparison